Anti-Hyperglycemic Agents in the Adjuvant Treatment of Sepsis: Improving Intestinal Barrier Function

Yi-Feng Wang, Jia-Wei Li, Da-Peng Wang, Ke Jin, Jiao-Jie Hui, Hong-Yang Xu Department of Critical Care Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, People's Republic of ChinaCorrespondence: Jiao-Jie Hui; Hong-Yang Xu, Email huijiaojie15@163....

Full description

Saved in:
Bibliographic Details
Main Authors: Wang YF (Author), Li JW (Author), Wang DP (Author), Jin K (Author), Hui JJ (Author), Xu HY (Author)
Format: Book
Published: Dove Medical Press, 2022-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b6e721c8ef494b32a90c0577b9fdaf8f
042 |a dc 
100 1 0 |a Wang YF  |e author 
700 1 0 |a Li JW  |e author 
700 1 0 |a Wang DP  |e author 
700 1 0 |a Jin K  |e author 
700 1 0 |a Hui JJ  |e author 
700 1 0 |a Xu HY  |e author 
245 0 0 |a Anti-Hyperglycemic Agents in the Adjuvant Treatment of Sepsis: Improving Intestinal Barrier Function 
260 |b Dove Medical Press,   |c 2022-06-01T00:00:00Z. 
500 |a 1177-8881 
520 |a Yi-Feng Wang, Jia-Wei Li, Da-Peng Wang, Ke Jin, Jiao-Jie Hui, Hong-Yang Xu Department of Critical Care Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, People's Republic of ChinaCorrespondence: Jiao-Jie Hui; Hong-Yang Xu, Email huijiaojie15@163.com; xhy1912@aliyun.comAbstract: Intestinal barrier injury and hyperglycemia are common in patients with sepsis. Bacteria translocation and systemic inflammatory response caused by intestinal barrier injury play a significant role in sepsis occurrence and deterioration, while hyperglycemia is linked to adverse outcomes in sepsis. Previous studies have shown that hyperglycemia is an independent risk factor for intestinal barrier injury. Concurrently, increasing evidence has indicated that some anti-hyperglycemic agents not only improve intestinal barrier function but are also beneficial in managing sepsis-induced organ dysfunction. Therefore, we assume that these agents can block or reduce the severity of sepsis by improving intestinal barrier function. Accordingly, we explicated the connection between sepsis, intestinal barrier, and hyperglycemia, overviewed the evidence on improving intestinal barrier function and alleviating sepsis-induced organ dysfunction by anti-hyperglycemic agents (eg, metformin, peroxisome proliferators activated receptor-γ agonists, berberine, and curcumin), and summarized some common characteristics of these agents to provide a new perspective in the adjuvant treatment of sepsis.Keywords: sepsis, sepsis-induced organ dysfunction, intestinal barrier, anti-hyperglycemic agents 
546 |a EN 
690 |a sepsis 
690 |a sepsis-induced organ dysfunction 
690 |a intestinal barrier 
690 |a anti-hyperglycemic agents 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Design, Development and Therapy, Vol Volume 16, Pp 1697-1711 (2022) 
787 0 |n https://www.dovepress.com/anti-hyperglycemic-agents-in-the-adjuvant-treatment-of-sepsis-improvin-peer-reviewed-fulltext-article-DDDT 
787 0 |n https://doaj.org/toc/1177-8881 
856 4 1 |u https://doaj.org/article/b6e721c8ef494b32a90c0577b9fdaf8f  |z Connect to this object online.